ALGORAE PHARMACEUTICALS ORD

Algorae Pharmaceuticals (ASX: 1AI) and private Indian company Cadila Pharmaceuticals have entered into a licence and supply agreement covering two new generic medicines for the Australian and New Zealand markets. The agreement will formalise an operational framework for the partnership and will see Algorae commence planning for Therapeutic Goods Administration (TGA) registration to enable commercialisation of […]

Algorae Pharmaceuticals (ASX: 1AI) has entered into an exclusive licencing agreement with Indian pharmaceutical manufacturer Sakar Healthcare to launch five generic oncology medicines into the Australian and New Zealand markets. The products will be marketed under the Algorae brand to meet the needs of the combined market, which analysts value at approximately $10 million per […]

Algorae Pharmaceuticals (ASX: 1AI) achieved a key milestone in the recent June quarter, locking in a strategic partnership with the Victorian Centre for Functional Genomics (VCFG) at Melbourne’s Peter MacCallum Cancer Centre. The partners are working on high-throughput experimental validation for 21 in silico predictions generated by the AI-enabled AlgoraeOS Version 1.0, alongside three drug […]

Algorae Pharmaceuticals (ASX: 1AI) has partnered with the Victorian Centre for Functional Genomics (VCFG) at the Peter MacCallum Cancer Centre in Melbourne to validate AI-predicted drug synergies using high-throughput screening. The companies will conduct a study to confirm the efficacy of drug combinations and dose ranges across four distinct cancer cell lines including glioblastoma, pancreatic […]